Literature DB >> 10066527

New antivirals - mechanism of action and resistance development.

J Balzarini1, L Naesens, E De Clercq.   

Abstract

In recent years, several novel treatment modalities emerged for a number of virus infections, including lamivudine for hepatitis B virus, abacavir, adefovir dipivoxyl and apropovir disprometil for human immunodeficiency virus, cidofovir for cytomegalovirus, and famciclovir (the oral prodrug of penciclovir) and cidofovir for other herpesviruses (i.e. herpes simplex virus and varicella-zoster virus). For all drugs, resistance eventually develops upon prolonged administration to the infected individuals, albeit at a varying extent. In addition, new mutations related to multidrug resistance have recently been identified.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10066527     DOI： 10.1016/s1369-5274(98)80086-6

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN： 1369-5274            Impact factor:   7.934


  9 in total

1.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Inhibition of virus DNA replication by artificial zinc finger proteins.

Authors:  Takashi Sera
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene.

Authors:  M van Zeijl; J Fairhurst; T R Jones; S K Vernon; J Morin; J LaRocque; B Feld; B O'Hara; J D Bloom; S V Johann
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 4.  Novel approaches in fighting herpes simplex virus infections.

Authors:  Sarah S Wilson; Esra Fakioglu; Betsy C Herold
Journal:  Expert Rev Anti Infect Ther       Date:  2009-06       Impact factor: 5.091

5.  PharmGKB summary: abacavir pathway.

Authors:  Julia M Barbarino; Deanna L Kroetz; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

6.  Development of CMX001 for the Treatment of Poxvirus Infections.

Authors:  Randall Lanier; Lawrence Trost; Tim Tippin; Bernhard Lampert; Alice Robertson; Scott Foster; Michelle Rose; Wendy Painter; Rose O'Mahony; Merrick Almond; George Painter
Journal:  Viruses       Date:  2010-12       Impact factor: 5.048

7.  In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newborns.

Authors:  Shu-Hong Lin; Youjin Wang; Stephen W Hartley; Danielle M Karyadi; Olivia W Lee; Bin Zhu; Weiyin Zhou; Derek W Brown; Erin Beilstein-Wedel; Rohan Hazra; Deborah Kacanek; Ellen G Chadwick; Carmen J Marsit; Miriam C Poirier; Sean S Brummel; Stephen J Chanock; Eric A Engels; Mitchell J Machiela
Journal:  AIDS       Date:  2021-08-01       Impact factor: 4.632

8.  Novel Isoxazolidine and γ-Lactam Analogues of Homonucleosides.

Authors:  Dorota G Piotrowska; Iwona E Głowacka; Dominique Schols; Robert Snoeck; Graciela Andrei; Joanna Gotkowska
Journal:  Molecules       Date:  2019-11-06       Impact factor: 4.411

Review 9.  Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.

Authors:  Lauren A Sadowski; Rista Upadhyay; Zachary W Greeley; Barry J Margulies
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.